Moderna (MRNA) Return on Sales (2017 - 2026)

Moderna (MRNA) has 10 years of Return on Sales data on file, last reported at 0.03% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.03%, up 6.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Sales retreated to 0.03% in Q1 2026 per MRNA's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q1 2022 and troughed at 0.09% in Q1 2025.
• A 5-year average of 0.02% and a median of 0.01% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2024 and 2026: Return on Sales fell 7 bps in 2024, then increased 6 bps in 2026.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then sank by 73 bps to 0.0% in 2023, then sank by 1602 bps to 0.01% in 2024, then dropped by 5 bps to 0.01% in 2025, then sank by 183 bps to 0.03% in 2026.
• Business Quant data shows MRNA's Return on Sales at 0.03% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.